{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:08:10Z","timestamp":1791479290589,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"DOI":"10.1186\/s12891-025-08402-8","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:59:44Z","timestamp":1740466784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip"],"prefix":"10.1186","volume":"26","author":[{"given":"Stephen J.","family":"DiMartino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fuerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetachi","family":"Emeremni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souhil","family":"Zaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamini","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Brener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fetell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ned","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Geba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"10182","key":"8402_CR1","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745\u201359.","journal-title":"Lancet"},{"issue":"1","key":"8402_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.33590\/emj\/10313855","volume":"3","author":"AM Valdes","year":"2018","unstructured":"Valdes AM, Stocks J. Osteoarthritis and ageing. Eur Med J. 2018;3(1):116\u201323.","journal-title":"Eur Med J"},{"issue":"3","key":"8402_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.joca.2020.01.002","volume":"28","author":"M Kloppenburg","year":"2020","unstructured":"Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. Osteoarthritis Cartilage. 2020;28(3):242\u20138.","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 1","key":"8402_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40266-019-00660-1","volume":"36","author":"C Cooper","year":"2019","unstructured":"Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyere O, Rannou F, Roth R, Uebelhart D, Reginster JY. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: What does the literature say? Drugs Aging. 2019;36(Suppl 1):15\u201324.","journal-title":"Drugs Aging"},{"issue":"4","key":"8402_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/art.21328","volume":"53","author":"C Lee","year":"2005","unstructured":"Lee C, Hunsche E, Balshaw R, Kong SX, Schnitzer TJ. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. Arthritis Rheum. 2005;53(4):510\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8402_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.joca.2016.01.135","volume":"24","author":"SR Smith","year":"2016","unstructured":"Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962\u201372.","journal-title":"Osteoarthritis Cartilage"},{"key":"8402_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/OARRR.S41940","volume":"5","author":"SD Taylor","year":"2013","unstructured":"Taylor SD, Everett SV, Taylor TN, Watson DJ, Taylor-Stokes G. A measure of treatment response: patient and physician satisfaction with traditional NSAIDs for osteoarthritis control. Open Access Rheumatol. 2013;5:69\u201376.","journal-title":"Open Access Rheumatol"},{"issue":"5","key":"8402_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/acr.23884","volume":"72","author":"MC Osani","year":"2020","unstructured":"Osani MC, Vaysbrot EE, Zhou M, McAlindon TE, Bannuru RR. Duration of symptom relief andearly trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(5):641\u201351.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7478","key":"8402_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/bmj.38273.626655.63","volume":"329","author":"JM Bjordal","year":"2004","unstructured":"Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329(7478):1317.","journal-title":"BMJ"},{"issue":"1","key":"8402_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.2010.507629","volume":"10","author":"A Lanas","year":"2011","unstructured":"Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf. 2011;10(1):45\u201354.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"8402_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/joca.2001.0510","volume":"10","author":"W Makarowski","year":"2002","unstructured":"Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10(4):290\u20136.","journal-title":"Osteoarthritis Cartilage"},{"issue":"10","key":"8402_CR12","first-page":"1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA. 2000;284(10):1247\u201355.","journal-title":"Celecoxib Long-term Arthritis Safety Study JAMA"},{"key":"8402_CR13","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.","journal-title":"BMJ"},{"issue":"11","key":"8402_CR14","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.41012","volume":"71","author":"P Dakin","year":"2019","unstructured":"Dakin P, DiMartino SJ, Gao H, Maloney J, Kivitz AJ, Schnitzer TJ, Stahl N, Yancopoulos GD, Geba GP. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: A phase IIb\/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"8402_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/annrheumdis-2020-217259","volume":"80","author":"P Dakin","year":"2021","unstructured":"Dakin P, Kivitz AJ, Gimbel JS, Skrepnik N, DiMartino SJ, Emeremni CA, Gao H, Stahl N, Weinreich DM, Yancopoulos GD, et al. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II\/III randomised clinical trial. Ann Rheum Dis. 2021;80(4):509\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"8402_CR16","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","volume":"23","author":"MC Hochberg","year":"2015","unstructured":"Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2015;23(Suppl 1):S18-21.","journal-title":"Osteoarthritis Cartilage"},{"key":"8402_CR17","unstructured":"Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017;35(Suppl 107)(5):85\u20137."},{"issue":"6","key":"8402_CR18","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","volume":"153","author":"RH Dworkin","year":"2012","unstructured":"Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain. 2012;153(6):1148\u201358.","journal-title":"Pain"},{"issue":"12","key":"8402_CR19","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1097\/j.pain.0000000000000333","volume":"156","author":"AH Tuttle","year":"2015","unstructured":"Tuttle AH, Tohyama S, Ramsay T, Kimmelman J, Schweinhardt P, Bennett GJ, Mogil JS. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015;156(12):2616\u201326.","journal-title":"Pain"},{"issue":"4","key":"8402_CR20","doi-asserted-by":"publisher","first-page":"100533","DOI":"10.1016\/j.ocarto.2024.100533","volume":"6","author":"SJ DiMartino","year":"2024","unstructured":"DiMartino SJ, Mei J, Schnitzer TJ, Gao H, Eng S, Winslow C, Ho T, Turner KC, Hassan HE, Patel Y, et al. A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip. Osteoarthritis and Cartilage Open. 2024;6(4):100533.","journal-title":"Osteoarthritis and Cartilage Open."},{"issue":"4","key":"8402_CR21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.16.4.494","volume":"16","author":"JH Kellgren","year":"1957","unstructured":"Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"8402_CR22","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833\u201340.","journal-title":"J Rheumatol"},{"key":"8402_CR23","unstructured":"Summary Minutes of the Arthritis Advisory Committee Meeting March 12, 2012 . https:\/\/web.archive.org\/web\/20161023214448\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM307879.pdf."},{"issue":"4","key":"8402_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med. 2009;28(4):586\u2013604.","journal-title":"Stat Med"},{"key":"8402_CR25","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.2147\/JPR.S310368","volume":"14","author":"P Schepman","year":"2021","unstructured":"Schepman P, Thakkar S, Robinson R, Malhotra D, Emir B, Beck C. Moderate to severe osteoarthritis pain and its impact on patients in the United States: a national survey. J Pain Res. 2021;14:2313\u201326.","journal-title":"J Pain Res"},{"issue":"3","key":"8402_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cger.2010.03.001","volume":"26","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;26(3):355\u201369.","journal-title":"Clin Geriatr Med"},{"key":"8402_CR27","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.2147\/JPR.S285124","volume":"13","author":"SR Nalamachu","year":"2020","unstructured":"Nalamachu SR, Robinson RL, Viktrup L, Cappelleri JC, Bushmakin AG, Tive L, Mellor J, Hatchell N, Jackson J. Multimodal treatment patterns for osteoarthritis and their relationship to patient-reported pain severity: A cross-sectional survey in the United States. J Pain Res. 2020;13:3415\u201325.","journal-title":"J Pain Res"},{"issue":"1","key":"8402_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13075-022-02759-0","volume":"24","author":"T Neogi","year":"2022","unstructured":"Neogi T, Hunter DJ, Churchill M, Shirinsky I, White A, Guermazi A, Omata M, Fountaine RJ, Pixton G, Viktrup L, et al. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study. Arthritis Res Ther. 2022;24(1):78.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"8402_CR29","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3899\/jrheum.131294","volume":"41","author":"EF Ekman","year":"2014","unstructured":"Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, Brown MT, West CR, Verburg KM. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014;41(11):2249\u201359.","journal-title":"J Rheumatol"},{"issue":"12","key":"8402_CR30","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s10067-016-3389-4","volume":"35","author":"S Mayes","year":"2016","unstructured":"Mayes S, Ferris AR, Smith P, Garnham A, Cook J. Professional ballet dancers have a similar prevalence of articular cartilage defects compared to age- and sex-matched non-dancing athletes. Clin Rheumatol. 2016;35(12):3037\u201343.","journal-title":"Clin Rheumatol"},{"key":"8402_CR31","doi-asserted-by":"publisher","first-page":"e5339","DOI":"10.1136\/bmj.e5339","volume":"345","author":"A Guermazi","year":"2012","unstructured":"Guermazi A, Niu J, Hayashi D, Roemer FW, Englund M, Neogi T, Aliabadi P, McLennan CE, Felson DT. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study (Framingham Osteoarthritis Study). BMJ. 2012;345:e5339.","journal-title":"BMJ."},{"issue":"3","key":"8402_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.39970","volume":"69","author":"A Guermazi","year":"2017","unstructured":"Guermazi A, Hayashi D, Roemer FW, Niu J, Quinn EK, Crema MD, Nevitt MC, Torner J, Lewis CE, Felson DT. Brief report: Partial- and full-thickness focal cartilage defects contribute equally to development of new cartilage damage in knee osteoarthritis: the multicenter osteoarthritis study. Arthritis Rheumatol. 2017;69(3):560\u20134.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"8402_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/annrheumdis-2012-201810","volume":"72","author":"FW Roemer","year":"2013","unstructured":"Roemer FW, Felson DT, Wang K, Crema MD, Neogi T, Zhang Y, Nevitt MC, Marra MD, Lewis CE, Torner J, et al. Co-localisation of non-cartilaginous articular pathology increases risk of cartilage loss in the tibiofemoral joint\u2013the MOST study. Ann Rheum Dis. 2013;72(6):942\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"8402_CR34","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/annrheumdis-2020-217363","volume":"79","author":"K Bacon","year":"2020","unstructured":"Bacon K, LaValley MP, Jafarzadeh SR, Felson D. Does cartilage loss cause pain in osteoarthritis and if so, how much? Ann Rheum Dis. 2020;79(8):1105\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8402_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1148\/radiol.14140991","volume":"274","author":"FW Roemer","year":"2015","unstructured":"Roemer FW, Kwoh CK, Hannon MJ, Hunter DJ, Eckstein F, Wang Z, Boudreau RM, John MR, Nevitt MC, Guermazi A. Can structural joint damage measured with MR imaging be used to predict knee replacement in the following year? Radiology. 2015;274(3):810\u201320.","journal-title":"Radiology"},{"issue":"1","key":"8402_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.2106\/JBJS.17.01657","volume":"101","author":"JS Everhart","year":"2019","unstructured":"Everhart JS, Abouljoud MM, Kirven JC, Flanigan DC. Full-Thickness cartilage defects are important independent predictive factors for progression to total knee arthroplasty in older adults with minimal to moderate osteoarthritis: Data from the osteoarthritis initiative. J Bone Joint Surg Am. 2019;101(1):56\u201363.","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"8402_CR37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.joca.2022.02.614","volume":"30","author":"FW Roemer","year":"2022","unstructured":"Roemer FW, Felson DT, Stefanik JJ, Rabasa G, Wang N, Crema MD, Neogi T, Nevitt MC, Torner J, Lewis CE, et al. Heterogeneity of cartilage damage in Kellgren and Lawrence grade 2 and 3 knees: the MOST study. Osteoarthritis Cartilage. 2022;30(5):714\u201323.","journal-title":"Osteoarthritis Cartilage"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-025-08402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-025-08402-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-025-08402-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:59:47Z","timestamp":1740466787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-025-08402-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8402"],"URL":"https:\/\/doi.org\/10.1186\/s12891-025-08402-8","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines and applicable International Council for Harmonisation Good Clinical Practice Guidelines. The institutional review board or independent ethics committee at each study center reviewed and approved the protocol, protocol amendments, informed consent form, and any other relevant documents (see the Supplementary Appendix for details).\u00a0All participants provided written informed consent to participate in the study. During routine blinded monitoring, prior to database lock, the sponsor suspected and identified non-compliance with good clinical practice at four sites comprising 219 patients. Patients from these sites were subsequently excluded from the modified full analysis set, as prespecified in the statistical analysis plan (see the Supplementary Appendix for details).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJD, HG, GPG, and PD are all employees of and shareholders in Regeneron Pharmaceuticals, Inc. who report having three patents pending with Regeneron Pharmaceuticals, Inc. SE, CE, TH, HEH, KCT, JC, YP, LB, NT, GM, and NB are all employees of and shareholders in Regeneron Pharmaceuticals, Inc. GV has served as a consultant for AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Sanofi\/Regeneron, and UCB; and as an Investigator for AbbVie, Image Analysis, Bristol Myers Squibb, Janssen, Lilly, Merck, MLKCDT, Novartis, Pfizer, and Sanofi\/Regeneron. TF owns equity in Clario, Inc, and has received grants or contracts from various pharmaceutical and biotechnology companies developing new drugs to treat osteoarthritis. JDD is an employee of and shareholder in Regeneron Pharmaceuticals, Inc. who reports having two patents pending with Regeneron Pharmaceuticals, Inc. SZ has no conflict of interest to disclose. MF is an employee of Teva Pharmaceuticals; has\u00a0been funded by Teva Pharmaceuticals for travel and attendance at investigator meetings; and has\u00a0received and holds stocks or stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}